APA (7th ed.) Citation

Perumal, J., Balabanov, R., Balcer, L., Galetta, S., Sun, Z., Li, H., . . . Fox, R. J. (2023). Long-Term Effectiveness and Safety of Natalizumab in African American and Hispanic/Latino Patients with Early Relapsing–Remitting Multiple Sclerosis: STRIVE Data Analysis. Neurology & Therapy, 12(3), 833. https://doi.org/10.1007/s40120-023-00461-0

Chicago Style (17th ed.) Citation

Perumal, Jai, Roumen Balabanov, Laura Balcer, Steven Galetta, Zhaonan Sun, Hanyue Li, Danette Rutledge, Robin L. Avila, and Robert J. Fox. "Long-Term Effectiveness and Safety of Natalizumab in African American and Hispanic/Latino Patients with Early Relapsing–Remitting Multiple Sclerosis: STRIVE Data Analysis." Neurology & Therapy 12, no. 3 (2023): 833. https://doi.org/10.1007/s40120-023-00461-0.

MLA (9th ed.) Citation

Perumal, Jai, et al. "Long-Term Effectiveness and Safety of Natalizumab in African American and Hispanic/Latino Patients with Early Relapsing–Remitting Multiple Sclerosis: STRIVE Data Analysis." Neurology & Therapy, vol. 12, no. 3, 2023, p. 833, https://doi.org/10.1007/s40120-023-00461-0.